Go Deep
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,416 | -5.4 | 3.12 | 0.37 | 1,735.16 |
| Oct 2026 | 19,379 | -5.4 | 3.15 | 0.37 | 1,745.13 |
| Oct 2026 | 19,106 | -5.7 | 3.35 | 0.37 | 1,857.44 |
| Oct 2026 | 19,229 | -5.6 | 3.26 | 0.37 | 1,802.43 |
| Oct 2026 | 18,818 | -6.1 | 3.56 | 0.37 | 1,972.18 |
| Oct 2026 | 18,441 | -6.6 | 3.84 | 0.37 | 2,126.73 |
| Oct 2026 | 18,306 | -6.8 | 3.94 | 0.37 | 2,176.34 |
| Oct 2026 | 18,351 | -6.7 | 3.90 | 0.37 | 2,154.00 |
Viridian Therapeutics, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 284,000.0 | 141,000.0 | 132,000.0 | 70,570,000.0 |
| Net Profit | -127,119,000.0 | -104,901,000.0 | -120,355,000.0 | -34,599,000.0 |
| EPS | -1.1 | -0.9 | -1.1 | -0.3 |
Viridian Therapeutics, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 70,849,000.0 | 302,000.0 | 314,000.0 | 1,772,000.0 | — |
| Net Profit | -342,601,000.0 | -269,949,000.0 | -237,734,000.0 | -129,874,000.0 | — |
| EPS | -3.3 | -3.1 | -5.3 | -4.0 | — |
Viridian Therapeutics, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 899,418,000.0 | 742,403,000.0 | 490,424,000.0 | 435,091,000.0 | — |
| Total Liabilities | 177,251,000.0 | 70,764,000.0 | 48,402,000.0 | 40,027,000.0 | — |
| Total Equity | 722,167,000.0 | 671,639,000.0 | 442,022,000.0 | 395,064,000.0 | — |
Owes vs Owns
Viridian Therapeutics, Inc. owed $0.40 for every $1 it owned in Jun 2026, up from $0.09 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.40× | 0.20× | 0.10× | 0.10× | 0.09× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Viridian Therapeutics, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 97.2%Other assets 2.3%
How it's funded — Dec 2025
Long-term debt 5.6%Payables 1.0%Other liabilities 13.1%Shareholders' equity 80.3%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 874.7 | 717.6 | 477.4 | 424.6 |
| Receivables | 0.0 | 0.0 | 0.1 | 0.1 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 3.6 | 3.4 | 3.3 | 2.9 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 21.1 | 21.4 | 9.6 | 7.5 |
| Liabilities & equity | ||||
| Short-term debt | 0.8 | 0.5 | 0.8 | 0.6 |
| Long-term debt | 49.9 | 20.6 | 20.2 | 4.6 |
| Payables | 8.7 | 2.1 | 2.2 | 14.2 |
| Other liabilities | 117.9 | 47.5 | 25.1 | 20.5 |
| Shareholders' equity | 722.2 | 671.6 | 442.0 | 395.1 |
| Net tangible assets | 722.2 | 671.6 | 442.0 | 395.1 |
Viridian Therapeutics, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -276,391,000.0 | -232,319,000.0 | -184,170,000.0 | -93,838,000.0 | — |
| Investing Activities | -37,563,000.0 | -228,651,000.0 | -94,252,000.0 | -115,126,000.0 | — |
| Financing Activities | 426,742,000.0 | 457,737,000.0 | 225,670,000.0 | 322,244,000.0 | — |